Resources from the same session
34MO - Outcomes according to FGFR alteration types in patients with a solid tumour treated by a pan-FGRF tyrosine kinase inhibitor in phase I/II trials
Presenter: Cedric Pobel
Session: Mini Oral session
Resources:
Abstract
Slides
Webcast
35MO - Discovery and characterization of selective, FGFR1-sparing, inhibitors of FGFR2/3 oncogenic mutations for the treatment of cancers
Presenter: Etienne Dardenne
Session: Mini Oral session
Resources:
Abstract
Webcast
36MO - Safety, tolerability and preliminary efficacy of poziotinib with twice daily strategy in EGFR/HER2 Exon 20 mutant non-small cell lung cancer
Presenter: Adrian Sacher
Session: Mini Oral session
Resources:
Abstract
Slides
Webcast
8MO - CC-90010, a reversible, potent oral bromodomain and extraterminal inhibitor (BETi) in patients (pts) with advanced solid tumours (aSTs) and relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Longer follow-up from parts A & B and first reporting of part C of a phase I study
Presenter: Victor Moreno
Session: Mini Oral session
Resources:
Abstract
Slides
Webcast
37MO - Concurrent mutations in STK11 and KEAP1 promote ferroptosis protection and SCD1 dependence in lung cancer
Presenter: Triparna Sen
Session: Mini Oral session
Resources:
Abstract
Slides
Webcast
38MO - IND.236: A Canadian Cancer Trial Group (CCTG) phase Ib trial of combined CFI-402257 and weekly paclitaxel (Px) in patients with HER2-negative (HER2-) advanced breast cancer (BC)
Presenter: Mihaela Mates
Session: Mini Oral session
Resources:
Abstract
Slides
Webcast
Invited discussant of abstracts 34MO, 35MO and 36MO
Presenter: Matthew Krebs
Session: Mini Oral session
Resources:
Slides
Webcast
Invited discussant of abstracts 8MO, 37MO and 38MO
Presenter: Susan Galbraith
Session: Mini Oral session
Resources:
Slides
Webcast
Live Q&A and discussion
Presenter: Fiona Thistlethwaite
Session: Mini Oral session
Resources:
Webcast